Product Highlight – Esbriet
- 48% relative risk reduction in mortality at 1 year with Esbriet vs placebo.(1-3)
- Extend life expectancy by 3 years in a lifetime disease model compared to best supportive care.(4)
- The only approved IPF treatment without a special warning or precaution in patients at higher CV risk or with known risk for bleeding.(1)
- Esbriet Pack insert for Malaysia (MyEsbriet1016_CDS7.0).
- Integrated Summary of Efficacy 2014. Data on file.
- King Te et al. N Engl J Med 2014; 370: 2083-2092.
- Nathan et al. Thorax 2016; (5): 429-35.
Full prescribing information is available upon request.